Streamlining Early Alzheimer Disease Detection With Remote Blood Biomarker Testing: Elisabeth Thijssen, PhD

WATCH TIME: 5 minutes

"The main advantage of our ecosystem is that we compress timelines. You really go through all these steps within a month. Then, the profile you get at the end of our ecosystem expedites the next steps because these patients now already have a flag—they’ve been biomarker-confirmed, most likely already showing some ongoing Alzheimer pathology. And thus, going into confirmatory testing and treatment is much faster."

At the 2025 Alzheimer’s Association International Conference, held July 27-30, in Toronto, Canada, Neurogen Biomarking presented research on ways to potentially accelerate early Alzheimer disease (AD) screening and care accessibility. The presented study aimed to validate the company’s new ecosystem that brings together in-home biomarker testing and cognitive assessment with virtual care. Findings from the study showed that the Neurogen ecosystem reduced the time from cognitive concerns to intervention by 4.5 years, changing the standard time from the emergence of cognitive concerns from years to months.^1,2

Among a total of 455 participants who received biomarker and digital cognitive testing, 26% had elevated phosphorylated tau (p-tau)217 concentrations and 80% had some form of cognitive impairment. Presented by Elisabeth Thijssen, PhD, chief scientific officer at Neurogen Biomarking, additional findings showed that Tasso could identify elevated p-tau217 with 88% accuracy and met the performance requirement for AD triaging in a broader patient population. The company noted that participants with elevated test results received follow up care virtually from board certified neurologists in days.

Following the presentation at AAIC 2025, Thijssen spoke with NeurologyLive^® to further talk about the company’s home-based ecosystem designed for the early detection of AD in patients 50 years and older who have cognitive concerns. She talked about the program including remote blood collection, cognitive testing, and access to board-certified neurologists. In 1 month, she noted that patients can receive a biomarker and cognitive profile that may guide them to the appropriate next step in care. Moreover, she discussed early results from community-based events that have shown faster referrals, earlier diagnosis, and in some cases, treatment initiation.

Click here for more coverage of AAIC 2025.

REFERENCES
1. Thijssen E. Remote Collection of Blood Biomarkers for Alzheimer’s disease and related disorders. Presented at: 2025 Alzheimer’s Association International Conference; July 27-31; Toronto, Canada. Scientific Session.
2. Neurogen Biomarking Virtual Care Ecosystem Cuts Time to Alzheimer’s Intervention by 4.5 Years, AAIC 2025 Presentation Findings Show. News Release. Neurogen Biomarking. Published July 28, 2025. Accessed July 29, 2025. https://www.globenewswire.com/news-release/2025/07/28/3122773/0/en/Neurogen-Biomarking-Virtual-Care-Ecosystem-Cuts-Time-to-Alzheimer-s-Intervention-by-4-5-Years-AAIC-2025-Presentation-Findings-Show.html